HEALIGRAFT SIGNED
Synergistic growth factor microenvironments for veterinary bone regeneration.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0HEALIGRAFT project word cloud
Explore the words cloud of the HEALIGRAFT project. It provides you a very rough idea of what is the project "HEALIGRAFT" about.
Project "HEALIGRAFT" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITY OF GLASGOW
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 149˙973 € |
| EC max contribution | 149˙973 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2017-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-08-01 to 2020-01-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITY OF GLASGOW | UK (GLASGOW) | coordinator | 149˙973.00 |
Map
Project objective
We propose a system that allows a safer delivery of recombinant human bone morphogenetic protein-2 (rhBMP2) for bone tissue engineering and have planned a veterinary trial in relevant conditions. We have teamed up with a team of veterinary surgeons and several industry and clinical partners for the appraisal of the proposal from a translational standpoint. rhBMP2 is a powerful growth factor (GF) essential in tissue morphogenesis and used to promote bone growth in clinical applications. Current clinical delivery has encountered serious complications associated with the high doses used. We have developed a system that allows the effective presentation of GFs in combination with the integrin binding domain of fibronectin (FN), promoting simultaneous and co-localised signalling between GF receptors and integrins. We have shown the ability of Poly(ethyl acrylate) PEA to organize FN and sequester rhBMP2 in synergy with the integrin binding region to direct stem cell differentiation. This technology enhances bone regeneration and vascularisation with lower rhBMP-2 doses. With this understanding we have engineered systems to regenerate a bone critical size defect in a murine model. Results were comparable to the higher doses used in the clinic, which makes the systems safe, effective and more competitive than current commercial products. The pathway to human applications requires strong financial commitments. We will explore the veterinary application of our technology and also, because of the conditions treated, as a demonstration towards application in humans. Overall, we will develop a safe and versatile bone system for clinical use in joint arthodesis and non- union bone defects, and we will set a route towards commercialization.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Zhe A. Cheng, Andres Alba-Perez, Cristina Gonzalez-Garcia, Hannah Donnelly, Virginia Llopis-Hernandez, Vineetha Jayawarna, Peter Childs, David W. Shields, Marco Cantini, Laura Ruiz-Cantu, Andrew Reid, James F. C. Windmill, Elena S. Addison, Sandra Corr, William G. Marshall, Matthew J. Dalby, Manuel Salmeron-Sanchez Nanoscale Coatings for Ultralow Dose BMP-2-Driven Regeneration of Critical-Sized Bone Defects published pages: 1800361, ISSN: 2198-3844, DOI: 10.1002/advs.201800361 |
Advanced Science 6/2 | 2020-04-04 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEALIGRAFT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HEALIGRAFT" are provided by the European Opendata Portal: CORDIS opendata.